ProCE Banner Activity

inMIND: A Phase III Study of Tafasitamab, an Anti-CD19 Antibody, Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

Conference Coverage
Slideset

The addition of tafasitamab to lenalidomide/rituximab significantly improved PFS vs placebo plus lenalidomide/rituximab for patients with R/R FL in this randomized, double-blind phase III inMIND trial.

Released: December 12, 2024

Expiration: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation